TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04833647

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardio-Pulmonary-Exercise-Testing (CPET)
Description: Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardio-Pulmonary-Exercise-Testing (CPET)
Description: Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardio-Pulmonary-Exercise-Testing (CPET)
Description: Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardio-Pulmonary-Exercise-Testing (CPET)
Description: Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
Study: NCT02477007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Study: NCT04065438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPOSORBER® LA-15
Description: LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia).
Study: NCT01673139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval exercise
Description: 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Given information on recommendations for physical activity.
Study: NCT04291963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGG + TUN
Description: In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTG + TUN
Description: In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
Study: NCT00305058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.05 mg/kg Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.0075 mg/kg intravenous
Study: NCT03257462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR001
Description: SPR001 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR001
Description: SPR001 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR001
Description: SPR001 Capsules
Study: NCT01109992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise plus Regadenoson (Lexercise)
Description: Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson (Lexiscan)
Description: Regadenoson Rubidium-82 Positron Emission Tomography
Study: NCT04644328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday
Description: Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
Study: NCT03186846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multimodal monitoring
Description: LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
Study: NCT02124967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A one hour exercise class including both aerobic activity and resistance training
Study: NCT02427529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low calorie diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low calorie diet
Study: NCT04254900

Intervention type: OTHER
Intervention: evaluating energy availability
Description: energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass

Intervention type: OTHER
Intervention: evaluating energy availability
Description: energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
Study: NCT00958035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic 0.03% solution
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Study: NCT02477007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol + ibuprofen
Description: Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Study: NCT00958035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle sterile solution (placebo)
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Study: NCT01693432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS (docetaxel+S-1)
Description: Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14
Study: NCT02477007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
Study: NCT03054961

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
Study: NCT01183845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy
Description: Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
Study: NCT02410070

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision
Description: The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision
Description: The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
Study: NCT01318785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Armsleeves
Description: Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Armsleeves
Description: Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.
Study: NCT03238664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo RARC
Study: NCT03202511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid Oral Tablet
Description: Included in arm/group descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate/Emtricitabine
Description: Included in arm/group descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/Emtricitabine
Description: Included in arm/group descriptions.
Study: NCT00545181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal acidifying gel (RepHresh)
Description: placement of vaginal acidifying gel into vagina to restore normal vaginal pH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole control
Description: oral metronidazole therapy alone
Study: NCT03276533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
Study: NCT03238664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Cystectomy
Description: Undergo RARC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo CEUS
Study: NCT01468337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Description: Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes).
Study: NCT04469595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iluvien 0.19 MG Drug Implant
Description: 0.19 mg Fluocinolone Acetonide Intravitreal Implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
Study: NCT02763930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GABA-rich cheese diet
Study: NCT02042157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bidet use
Description: Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bidet use
Description: Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular toileting
Description: Patients in the control arm will toilet as usual.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular toileting
Description: Patients in the control arm will toilet as usual.
Study: NCT03673969

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Surgical method of gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Surgical method of gastric bypass
Study: NCT01077297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezosentan
Description: single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
Study: NCT04570839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 in combination with BMS-986207 and nivolumab.
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 in combination with BMS-986207 and nivolumab.
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 in combination with BMS-986207 and nivolumab.
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 in combination with BMS-986207 and nivolumab.
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 in combination with BMS-986207 and nivolumab.
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
Study: NCT04036695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ insertable cardiac monitoring system
Description: A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
Study: NCT03305965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
Study: NCT02074241

Intervention type: OTHER
Intervention: Expression analysis
Description: Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.

Intervention type: OTHER
Intervention: Expression analysis
Description: Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
Study: NCT01067105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide HFA 160 μg
Description: ciclesonide HFA 160 μg once daily
Study: NCT02036073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
Study: NCT00454337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF + EFV or LPV/R +T20
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF + EFV or LPV/R
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
Study: NCT02351414

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty (EVOLUTION®)
Study: NCT01144065

Intervention type: PROCEDURE
Intervention: Hair sampling for the measurement of cortisol and testosterone
Description: Hair sampling for the measurement of cortisol and testosterone

Intervention type: PROCEDURE
Intervention: Hair sampling for the measurement of cortisol and testosterone
Description: Hair sampling for the measurement of cortisol and testosterone

Intervention type: PROCEDURE
Intervention: Hair sampling for the measurement of cortisol and testosterone
Description: Hair sampling for the measurement of cortisol and testosterone
Study: NCT01074268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
Study: NCT04074941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Intervention include low sodium or usual sodium diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Intervention include low sodium or usual sodium diet
Study: NCT00828568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% manufactured by Taro
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara - Imiquimod 5%
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks